Assistant Professor Eliza Fong’s team develops new platform that significantly reduces drug testing and screening time for cancer patients
 In collaboration with the National Cancer Centre Singapore, Dr. Fong and team have developed a novel platform that can significantly reduce the time needed to determine the efficacy of anti-cancer drugs. In this first-of-its-kind technology, patient tumours resected from surgery can now be grown using bioengineered hydrogels and better preserved ex vivo (outside of the body) compared to standard approaches, potentially accelerating the process for drug screening and testing for individual cancer patients.
The results of this study were published in the journal Biomaterials on 20 January 2024.
More details of this study can be found here: NUS News (https://news.nus.edu.sg/singapore-scientists-develop-new-platform-that-significantly-reduces-drug-testing-and-screening-time-for-cancer-patients/) and on the Straits Times (https://www.straitstimes.com/singapore/s-pore-scientists-create-way-to-preserve-cancer-tumour-cultures-for-better-targeted-drug-testing)
